Safety and Efficacy of YH14617 in Diabetes Mellitus
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617
after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to
investigate the optimal recommended dosage. Study period is 20 weeks including 12 weeks of
treatment period and 8weeks of follow-up period without treatment.